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gp43 is the major diagnostic antigen of Paracoccidioides brasiliensis, the agent of paracoccidioidomycosis
(PCM) in humans. In the present study, cDNA of the gp43 gene (PbGP43) was obtained by reverse transcrip-
tase PCR, inserted into a pGEX vector in frame with the glutathione S-transferase (GST) gene, and expressed
in Escherichia coli as inclusion bodies. Immunoblotting showed that all sera from patients with chronic pul-
monary and acute lymphatic forms of PCM reacted with the recombinant fusion protein of the mature gp43
(381 amino acids). Reactivity with fusion proteins containing subfragments of the N-terminal, internal, or C-
terminal regions occurred eventually, and the C-terminal region was the most antigenic. Lack of reactivity with
the subfragments may be due to the conformational nature of the gp43 epitopes. Sera from patients with asper-
gillosis, candidiasis, and histoplasmosis did not react with the gp43-GST fusion protein. Our results suggest
that recombinant gp43 corresponding to the processed antigen can be a useful tool in the diagnosis of PCM.
Paracoccidioidomycosis (PCM) in humans is a systemic
granulomatous mycosis caused by Paracoccidioides brasiliensis,
a dimorphic fungus. Infection starts by inhalation of fungal
propagules, which reach the pulmonary alveolar epithelium
and transform into the parasitic yeast form. Chronic PCM is
the most common form and preferentially affects male adults.
It evolves gradually in the lungs but can involve other organs,
often being associated with mucous membranes and skin le-
sions. Acute and subacute PCM forms affect both sexes,
progress rapidly, and disseminate through the lymphatic sys-
tem, with lymph node enlargement and, in severe cases, in-
tense hepatosplenomegaly and damage to other organs.
Patients with severe PCM forms are deficient in the protec-
tive cellular immunity against P. brasiliensis, which can then
grow in large scale, increasing the antigenic load and the anti-
body response against fungal antigens. At this stage the anti-
bodies are no longer protective (8) but are useful in the diag-
nosis and prognosis of PCM. The main antigenic component
described for P. brasiliensis is the exocellular glycoprotein gp43
(17), which is recognized by most sera from PCM patients (5,
24). Successful treatment is reflected in a decrease of circulat-
ing anti-gp43 antibodies and restoration of cellular immunity
(8, 11, 19).
gp43 is also an immunodominant antigen for cellular immu-
nity in humans and experimentally infected animals (20, 21). In
murine PCM, native gp43, the 15-amino-acid peptide P10 con-
taining the T-cell epitope, and the gp43 gene were able to
protect against intratracheal challenge with virulent P. brasil-
iensis by eliciting a gamma interferon-producing Th-1 response
(14, 25). In addition, the glycoprotein may be involved in
pathogenesis, since it binds to murine laminin (27), and lami-
nin-coated yeast cells have increased virulence. A murine anti-
gp43 monoclonal antibody was able to modulate the infection
by these cells in a hamster intratesticular PCM model (9).
The open reading frame of the gp43 gene (PbGP43) is within
a 1,329-bp DNA fragment comprising two exons separated by
a 78-bp intron (6). The gene encodes a protein of 416 amino
acids, which includes a signal peptide of 35 residues. The se-
quence of the mature or exocellular gp43 starts with an alanine
residue. The antigen contains a single N-linked oligosaccharide
chain (1), but specific antibodies from PCM patients are pref-
erentially directed to conformational peptide epitopes (15).
Anti-gp43 monoclonal antibodies could detect at least three
sets of epitopes in inhibition assays (9, 16). Polymorphism in
the gp43 sequence has been observed at both the protein (13,
17) and gene (12) levels. Isoforms with neutral isoelectric
points, like those of the gp43 from isolate B-339 of P. brasil-
iensis, are more commonly found and are mostly reactive with
patient’s antibodies (22).
Although gp43 is a PCM-specific antigen in immunological
tests that preserve its native conformation, it contains terminal
galactofuranose units in the oligosaccharide chain (1), which
can be a source of cross-reactivity in tests that use the immo-
bilized antigen, such as enzyme-linked immunosorbent assays
(15). The expression of recombinant proteins in bacteria can
be useful because they are unglycosylated. The present work
describes the immunological reactivity of glutathione S-trans-
ferase (GST) fusion proteins with the entire gp43 sequence
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and subfragments of the N-terminal, internal, and C-terminal
regions, which were expressed in bacteria.
MATERIALS AND METHODS
Synthesis of the gp43 cDNA. The coding sequence of the gp43 antigen was
obtained by reverse transcriptase PCR as described previously (14). Briefly,
cDNA was reverse transcribed from total RNA isolated from P. brasiliensis B-339
(6, 7) by using an oligo(dT) standard primer and was used as a template in PCRs.
The full coding region of the gp43 antigen was synthesized by using the internal
primer 490 (5-GTCAGATCTATCATGAATTTTAGTTCCTTAAC-3), con-
taining a BglII site before the ATG start codon, and the downstream primer 491
(5-ACGTCGACTCACCTGCATCCACCATACTT-3), with a SalI site imme-
diately after the TGA stop codon. The processed or mature gp43 was synthesized
with the upstream primer 690 (5-CAGTCGACAAGCAGGATCAGCAATAT
AT-3), containing a SalI site before the alanine codon GCA, and the down-
stream primer 691 (5-GCGGTACCTCACCTGCATCCACCATA-3), with a
KpnI site immediately after the TGA stop codon. The PCR fragments generated
with primers 490 and 491 (1,250 bp) and with primers 690 and 691 (1,145 bp)
were extracted from the agarose gels by using the Sephaglass kit (Amersham
Pharmacia) and cloned using the pMOS T Blue vector kit (Amersham Pharma-
cia). DNA sequencing of the cloned fragments confirmed their identity with the
original PbGP43 sequence deposited in GenBank (accession number U26160).
The gp43 gene subfragment containing the 5 region (329 bp) was obtained by
BglII and BamHI restriction of the gp43 cDNA encoding the full molecule. The
subfragments containing the internal region (492 bp) and 3 region (375 bp) were
obtained as described previously (6).
Expression and serum reactivity of the recombinant gp43. The gp43 cDNA
fragments and subfragments were subcloned into pGEX plasmids (Amersham
Pharmacia) in frame with the GST gene. The fusion proteins were expressed in
Escherichia coli DH5 upon induction with 1 mM IPTG (isopropyl--D-thioga-
lactopyranoside). Bacteria were cleaved by boiling in reduced sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) sample buffer, the ex-
tracts were separated by SDS-PAGE (10) and transferred to nitrocellulose filters
(26), and the membranes were used in immunoblot reactions. The reactivity of
the recombinant proteins was tested with rabbit anti-gp43 antiserum (1:5,000)
(18) and with sera from patients with PCM. Immunocomplexes of rabbit anti-
bodies were evidenced with goat anti-rabbit immunoglobulin G (IgG)–peroxi-
dase conjugates and developed with diaminobenzidine (DAB). Reactions with
patients’ sera (1:300) were detected with biotinylated anti-human IgG (Amer-
sham Pharmacia) at a 1:1,000 dilution and streptavidin-peroxidase (Amersham
Pharmacia) at a 1:1,000 dilution and developed with DAB. Alternatively, the
reactivity of recombinant gp43-GST fusion proteins with patients’ sera (1:1,000)
was detected by chemiluminescence (2) with biotinylated anti-human IgG devel-
oped with luminol. Membranes were exposed (3 min) to an X-ray film (Hyper-
film-MP; Amersham Pharmacia).
Sera. Anti-gp43 rabbit immune serum was previously obtained by Puccia et al.
(18). Patients’ sera were kindly provided by Arnaldo Colombo and Zoilo Pires de
Camargo (Universidade Federal de Sa˜o Paulo), by Carlos da Silva Lacaz (Uni-
versidade de Sa˜o Paulo), and by Gilson Freitas da Silva (Faculdade de Medicina,
Ribeira˜o Preto, Universidade de Sa˜o Paulo). Patients with chronic PCM were all
male, were 44 to 66 years old (except one was 29 years old), and had pulmonary
PCM. Patients with acute PCM were 43% female, had the disseminated lym-
phatic form, and were 10 to 38 years old. Most of the patients had active and
severe PCM, with high antibody titers, and many were under treatment.
RESULTS
The PbGP43 coding sequence was inserted in frame with the
GST gene of the pGEX vector and expressed as gp43-GST
fusion proteins in E. coli. Figure 1A shows a schematic repre-
sentation of the constructs corresponding to the fusion pro-
teins of the full (pGF) and processed or mature (pGM) gp43
(416 and 381 amino acids, respectively), as well as the subfrag-
ments including the first 110 amino acids of the N-terminal
region (pGN), the internal sequence from amino acid 112 to
272 (pGI), and the C-terminal region from amino acid 288 to
411 (pGC). The mature protein corresponds to the sequence
of the gp43 isolated from culture supernatants, as determined
by N-terminal analysis (6). The five recombinant products were
expressed as major insoluble cytoplasmic proteins, as revealed
by Coomassie blue-stained SDS-polyacrylamide gels of solu-
ble and insoluble components of the bacterial extracts (not
shown). Induction of protein expression with lower concentra-
tions of IPTG or at 30°C, for various time intervals, did not
reduce the degree of insolubility.
In immunoblots, the bands corresponding to pGF (73 kDa),
pGM (70 kDa), pGN (37 kDa), pGI (43 kDa), and pGC (40
kDa), but not GST alone, were all recognized by a rabbit
anti-gp43 immune serum, as shown in Fig. 1B. These proteins
were also recognized by a rabbit anti-GST antiserum (not
shown) and migrated in SDS-PAGE with apparent molecular
masses near those expected for GST fusion products. The
reactive bands that can be seen in Fig. 1 migrating faster than
pGF and pGM are either degradation products or truncated
recombinant proteins.
The reactivities in immunoblots of the gp43-GST proteins
pGM, pGN, pGI, and pGC were tested with sera from PCM
patients, all of which reacted well with native gp43 (not
FIG. 1. (A) Schematic representation of the gp43-GST recombinant fusion proteins pGF, pGM, pGN, pGI, and pGC. The numbers correspond
to the amino acids in the gp43 sequence, starting from the initial methionine (amino acid 1). (B) The indicated gp43-GST fusion proteins were
expressed in E. coli; the reactivity of bacterial extracts was tested by immunoblotting with a rabbit polyclonal anti-gp43 serum (1:5,000) and
detected with DAB. Reactions with rabbit preimmune serum were negative and are not shown. GST, bacterial extract containing recombinant
GST; gp43, native gp43. Sizes of molecular mass markers are indicated in kilodaltons.
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shown). The protein pGM was recognized by all of the sera
tested, which included 13 from patients with chronic PCM and
14 from patients with acute PCM. Figure 2A shows the immu-
noblotting of six sera from patients with chronic PCM (Fig.
2A) and seven sera from patients with acute PCM (Fig. 2B)
with total bacterial lysates containing pGM as a major protein
component. Some sera (serum 1255, for example) also reacted
with bacterial proteins of high molecular weight, which were
seen in the bacterial extract expressing only GST (control
lanes). Reactive protein bands migrating faster than pGM can
be either proteolytic products from pGM or expressed trun-
cated forms. When bacterial lysates containing pGM were
tested for reactivity against sera from patients with candidiasis,
aspergillosis, and histoplasmosis and from a healthy individual,
only nonspecific bacterial components were observed (Fig.
2C).
Since the reactions with pGN, pGI, and pGC were either
absent or poorly seen in immunoblots developed with DAB,
the assays with individual sera were carried out later using a
more sensitive detection system. When the immunocomplexes
were detected by chemiluminescence, we observed reactivity
with all of the subfragments, although in only a few instances
did an individual serum react with all of them. One example
can be seen in Fig. 3A: serum 1131 (acute PCM) recognized all
of the fusion proteins (pGM, pGN, pGI, and pGC), but the
reactivity with pGN was weaker than that with the other re-
combinants. Serum 4 (acute PCM) reacted well with pGM,
pGN, and pGC but little with pGI (Fig. 3A). It is of note that
only three sera from patients with chronic PCM reacted with
any gp43 subfragment, all of them with pGC, while several sera
from patients with acute PCM recognized at least one subfrag-
ment. Sera 6442 and 6682 from patients with chronic PCM
reacted well with pGC as well as pGM (Fig. 3A). It was inter-
esting that all sera that were able to recognize gp43 subfrag-
ments always reacted at least with pGC.
Serum 1293 (acute PCM) reacted with pGM and pGC and
weakly with pGI. When the serum of the same patient was
tested after the first month of treatment (serum 1293t), the
reactivity with pGC was negative after 1 min of exposure and
was detectable after overexposure for 6 min (Fig. 3B).
DISCUSSION
The first recombinant clone expressing the gp43 protein
recognizable by human antibodies was reported by Taba et al.
(23). Subsequently, Cisalpino et al. (6) showed the reactivity of
FIG. 2. The pGM fusion protein (lanes on the left) and GST alone (control lanes on the right) were expressed in E. coli, and the reactivity of
bacterial extracts was tested by immunoblotting. The positions of pGM and GST are indicated. (A and B) Sera (1:300) from patients with chronic
(A) and acute (B) PCM. Serum numbers are indicated above the lanes. (C) Sera from patients with other mycoses (cand, candidiasis; asp,
aspergillosis; hist, histoplasmosis) and from a healthy individual (NHS). PCM serum 1375, from a patient with chronic PCM, was included in panel
C for comparison. The reactions were detected with DAB.
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gp43-GST recombinants of the internal and C-terminal regions
of the antigen with a pool of sera from PCM patients and a
rabbit anti-gp43 antiserum. This reactivity confirmed that the
gene cloned and sequenced by those authors corresponded to
that of the gp43 antigen. In the present work, four gp43-GST
recombinant proteins were studied, i.e., the mature processed
antigen (pGM) and subfragments of the N-terminal (pGN),
internal (pGI), and C-terminal (pGC) regions. These proteins
reacted in immunoblotting with an anti-gp43 rabbit antiserum,
and all the sera from PCM patients recognized the recombi-
nant fusion protein of the mature antigen.
Most of the sera tested reacted only with the mature recom-
binant protein, and epitope preferences could not be mapped.
This general pattern of reactivity was also observed with an
anti-gp43 murine monoclonal antibody that reacted with pGM
and was negative with the fusion proteins of the distinct re-
gions (not shown). This result is not surprising, since the mono-
clonal antibody tested recognizes conformational peptide
epitopes (9, 16). On the other hand, the gp43-GST proteins
were expressed in bacteria as inclusion bodies, and their native
conformation could have been changed due to the fusion with
GST, lack of glycosylation, insolubility, denaturation in SDS-
PAGE, and blotting. Therefore, the low percentage of human
sera reacting with the gp43-GST subfragments may be due to
loss of conformational epitopes, which are predominantly rec-
ognized by human sera as well (15, 16).
Out of the 27 sera tested, however, some (generally from
untreated patients with the lymphatic form of PCM) reacted
with gp43-GST subfragments, indicating the presence of B-cell
epitopes throughout the molecule. The Jameson-Wolf anti-
genic index predicts several potential antibody binding hydro-
philic regions along gp43, according to the Protean graphic
analysis of DNASTAR. According to the Emini plot, se-
quences with highest probability of surface expression in the
protein are in the internal (amino acids 222 to 228 and 259 to
264) and, more remarkably, C-terminal (amino acids 356 to
364) regions. Not surprisingly then, many of the PCM patients’
sera reacted with the C-terminal region, as well as with the
entire molecule. A patient’s serum tested after 1 month of
chemotherapy lost its reactivity with the C-terminal region,
thus correlating this specific antibody response with active in-
fection. In fact, gp43 has been considered a prognostic marker
for PCM, so that patients undergoing treatment have decreas-
ing anti-gp43 titers (3, 4, 11). It is possible that the earlier
antibodies to disappear in the successfully treated patients are
those against the C-terminal epitope(s) of gp43. On the other
hand, in our analysis most sera from patients with chronic
PCM did not react with subfragments, and that might be due to
the fact that these sera were mostly from treated individuals,
while the patients with acute PCM were generally untreated
when the sera were collected.
In the present study, we found that all sera from PCM
patients recognized the mature gp43-GST fusion protein as
determined by immunoblotting, while nonrelated sera were
negative. Such reactivity confirms that peptide rather than
carbohydrate epitopes are immunodominant in gp43 for anti-
body response, as previously shown with the deglycosylated
antigen (15, 16). This analysis also suggests that recombinant
gp43 can be a useful tool in the diagnosis of PCM, especially if
FIG. 3. gp43-GST recombinant proteins (M, pGM; N, pGN; I, pGI; C, pGC) and GST were expressed in E. coli, and the reactivity of bacterial
lysates was tested by immunoblotting with sera (1:1,000) from PCM patients. Detection was carried out by chemiluminescence assay. (A) Reactions
with sera 4 and 1131 (acute PCM) and 6642 and 6682 (chronic PCM). (B) Reactions with serum from patient 1293 (acute PCM) before and after
(1293t) 1 month of treatment, with membrane exposures of 1, 3, and 6 min as indicated. Sizes of molecular mass markers are indicated in
kilodaltons.
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expressed as soluble protein that can be purified and used in
tests such as enzyme-linked immunosorbent assays.
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